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Angiotensin-dependent gene expression in the developing rat
kidney. We aimed to identify genes involved in the growth effects
of angiotensin II (Ang II) during kidney development. In rats
treated from birth with the Ang II type-1 receptor blocker
losartan, expression of transforming growth factor b1 (TGF-b1),
platelet-derived growth factor B (PDGF-B), vascular endothelial
growth factor (VEGF), and epidermal growth factor (EGF), as
measured by Northern blot, did not change significantly (N 5 4 to
6 per group each). Differential display methods, used to identify
genes with Ang II-dependent expression, produced mostly false
positives. We identified one novel rat partial cDNA, termed
AD.5, that is related to a human orphan receptor. AD.5 was
expressed in a developmentally regulated pattern and may be
involved in kidney development and/or the trophic actions of
Ang II.
The vasoconstrictor peptide angiotensin II (Ang II) is
necessary for the normal development of the kidney, in
particular for renal vessels and tubules [1–4]. To identify
genes exhibiting Ang II-dependent expression during kid-
ney development, we studied the expression of growth
factors [transforming growth factor b1 (TGF-b1), platelet-
derived growth factor B (PDGF-B), vascular endothelial
growth factor (VEGF), and epidermal growth factor
(EGF)] after blockade of the Ang II type-1 receptor in
neonatal rats using polymerase chain reaction (PCR)-based
differential display (DD) [5] and RNA fingerprinting [6].
METHODS
Neonatal Sprague-Dawley rats (Hilltop Farms, Scotts-
dale, PA, USA) were treated from the day of birth with
daily subcantaneous injections of the Ang II type-1 recep-
tor antagonist losartan (25 mg/kg) or saline (N 5 20 each)
as described [1]. Rats were sacrificed on day 13, and the
kidney RNA was extracted. Northern blots [3] loaded with
10 to 20 mg total RNA or 2 mg poly(A1) RNA were
hybridized with a 206-bp probe for VEGF, with full-length
cDNAs for renin, PDGF-B, TGF-b1, and EGF, as well as
with DD cDNA fragments. Probes were labeled with
a[32]P-CTP (DuPont NEN, Boston, MA, USA) by random
prime or PCR labeling [3]. Signals were quantified by a
PhosphoImage screen (Molecular Dynamics, Sunnyvale,
CA, USA). Data were subjected to analysis of variance and
are expressed as mean 6 SEM.
DD-PCR was performed using the polyA1-anchored
primer 59-TTTTTTTTTTTTMA-39 for reverse transcrip-
tion and PCR; cycling conditions and arbitrary 10mer
primers were selected as described by Liang et al [5].
DD-PCR products were displayed on a 5% acrylamide-
urea gel; differentially expressed bands were eluted and
reamplified [5]. The reamplified PCR products were cloned
into the pCNTR vector (5 Prime-3 Prime Inc., Boulder,
CO, USA). In addition, we also used a modification of the
RNA fingerprinting method [6]. Poly(A1)-RNA was used
for reverse transcription; primers, reverse transcription,
and PCR conditions were adapted from a modification of
the method [7]. Sequencing was performed using the
Sequenase 2.0 kit (Amersham, Arlington Heights, IL,
USA).
RESULTS AND DISCUSSION
Neonatal losartan treatment reduced the kidney weight/
body weight ratio (5.13 6 0.09 vs. 5.52 6 0.11 mg/g in
controls, N 5 20 each, P , 0.05). Kidney renin expression
was increased 35-fold by losartan (321 6 40 vs. 9 6 1
arbitrary units in controls, N 5 6 each, P , 0.05). However,
the expression of TGF-b1, PDGF-BB, VEGF, and EGF
(N 5 4 to 6 per group) was unchanged by losartan.
Five differential display PCR fragments exhibiting ap-
parent down-regulation by losartan in a reproducible man-
ner were tested by Northern blotting. For one fragment, no
expression was detected, whereas three further fragments
showed unchanged expression. Only one fragment, termed
AD.5, exhibited a slightly lower expression in losartan-
treated kidneys than in controls (Fig. 1). Using the RNA
fingerprinting method, approximately 80% of apparently
differential bands were not reproducible. Five fragments
with reproducible apparent differential expression were
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tested by Northern blotting. All but one labeled multiple
transcripts, and none were differentially expressed. With
the exception of AD.5, all cloned DD-PCR or RNA
fingerprinting bands contained more than one (3–7) cDNA
sequences of the same length, all containing the expected
primer sequences at both ends.
Expression of the 2.0-kb transcript of AD.5 was highest
in lung, kidney, and heart and was weakest in brain (Fig. 1).
Age-dependent expression of AD.5 in the kidney was found
in 2-week-old rats.adult.newborn (Fig. 1). Of the 307
nucleotide sequence of AD.5, the 59 133 bases exhibited
86% identity to a human seven-transmembrane orphan
receptor (GenBank accession #AF000546). A hypothetical
translation yielded 88% identity and 93% similarity of the
amino acid sequences of AD.5 and the orphan receptor
(Fig. 1). The function and the ligand of this receptor are
unknown. A chicken homologue (termed 6H1) of this
orphan receptor was initially considered to be a P2Y
purinoceptor [8], but recent reports refute this [9].
In this study, we screened the expression of various
growth factors in kidneys with an abnormal structure due to
neonatal Ang II receptor blockade [1]. Although some of
these factors are thought to be involved in the trophic
actions of Ang II [10], we found no altered expression. Our
findings do not exclude more subtle or localized changes in
the expression of these growth factors, as described by
some authors in similar models [2]. However, massive
structural abnormalities are present in rats treated neona-
tally with losartan [1], and subtle or equivocal changes in
the expression of growth factors are not likely to explain
these striking effects of Ang II receptor blockade [2–4].
We turned to PCR-based methods to identify genes that
are down-regulated by neonatal Ang II receptor blockade.
Both DD-PCR [5] and a modification [7] of RNA finger-
printing [6] produced mostly false positives. Moreover,
more than one sequence was almost invariably found after
cloning cDNA fragments. In our view, these pitfalls limit
the use of these methods for systematic comparison of gene
expression in complex animal tissues such as the kidney.
These PCR-based methods are very useful for identifying
differentially expressed genes in cell culture systems [1].
DD-PCR of cultured kidney cells has previously identified
novel genes with cell-specific expression [11, 12].
Despite the high rate of false positives produced by
DD-PCR, we did identify novel rat cDNAs that were
down-regulated by losartan. One novel gene, termed
WOT.1 [13], will be described in detail elsewhere. Here, we
describe the partial sequence of AD.5, which appears to be
the rat homologue of a previously cloned human orphan
receptor. Because the function of this orphan receptor is
unknown, we cannot draw conclusions on the possible
function of the AD.5 product. However, the AD.5 tran-
script exhibits organ-specific and developmentally regu-
lated expression, and its expression is affected by neonatal
Fig. 1. Upper panel: Northern blot hybridized with AD.5 probe. Two mg poly(A1)-RNA was loaded per lane. A denotes tissue from adult (3 months),
N from newborn (,24 hr) rats. Los indicates 13-day-old rats treated with losartan, Con age-matched control rats. Lower panel: Alignment of amino acid
sequences derived from conceptual translation of the 59 132 nucleotides of AD.5, and the carboxyterminal 44 amino acids of a human orphan
seven-transmembrane receptor (GenBank accession #AF000546, putative P2Y purine receptor).
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losartan treatment. Thus, the AD.5 product may be in-
volved in the development of structure and function of the
kidney and/or in the trophic actions of Ang II.
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